Milbank LLP has provided comprehensive legal advice to the fund German Equity Partners IV, which is managed by the independent German investment company ECM Equity Capital Management GmbH ("ECM"), on the sale of its majority stake in Uroviva Group to Affidea B.V.
Uroviva Group is one of the leading private providers of medical services in the fields of urology, gynecology and oncology in Switzerland. It operates 16 locations across the cantons of Zurich, Lucerne, Zug, Solothurn and Aargau, employing approximately 250 people. Its range of services includes both outpatient care and inpatient treatments.
Affidea B.V. is a leading pan-European provider of specialized healthcare services and a portfolio company of the publicly listed Groupe Bruxelles Lambert S.A.
Since 1995, ECM has been a growth partner for mid-sized enterprises and entrepreneurs in German-speaking Europe and has raised the five private equity funds GEP I-V with aggregate equity commitments of more than €1 billion. ECM currently invests out of its fifth fund GEP V (€325 million). The funds invest primarily in leading mid-market companies in the context of succession solutions, partnership transactions and corporate spin-offs.
The Milbank team that advised ECM on the corporate and tax aspects of the transaction was led by partner Michael Bernhardt and included associates Sarah-Maria Resch, Andreas Rief and Josephine Schuster (all Corporate/M&A, Frankfurt) as well as partner Matthias Schell and associate Nikolas Wolf (both Tax, Munich).
